Below The Knee | Market Signal

Enforcement Escalation Meets Reimbursement Clarity

The Department of Justice indicted a Nevada physician this week on a $95 million CAMP fraud scheme involving medically unnecessary amniotic wound allografts and Anti-Kickback Statute violations. It's the first prosecution by the newly active West Coast Health Care Fraud Strike Force. Translation: federal enforcement of wound care and skin substitute fraud just escalated nationally.

That lands hard on CAMP-pure plays. The market knows it. SNWV down 17.35%, SNOA down 7.26%, MDWD down 5.98% on the week. Smaller-cap companies carrying concentrated CAMP exposure are pricing in higher compliance risk and the reality that the easy reimbursement days are over.

But here's what the fund moves actually show. The top performers this week aren't the CAMP players. They're companies with reimbursement clarity, diversified portfolios, or adjacent expansion plays. Solventum up 4.55%, Globus Medical up 4.47%, Aroa up 5.37% on US reimbursement clarity for Symphony. Orthofix raising full-year guidance on the back of Medicare reimbursement restoration for bone growth stimulators.

So the story isn't "CAMP is dying." The story is that enforcement is real, reimbursement is under Congressional scrutiny, and the market is bifurcating: CAMP-pure losers pricing in compliance risk, versus diversified and adjacent-play winners with clear reimbursement pathways.

One week, two stories. Same category, opposite trajectories.

Here's the week.

Note - Wounds Australia is five days away, and IPAWS, where BTK is the official Market Intelligence platform, is only 28 days away. Conference season is upon is, but Below The Knee Intelligence is tracking all major wound care events through the fall conference season. See the full calendar at the end.

Regulatory | DOJ Indicts Nevada Physician in $95M Medicare Wound Care Fraud Scheme

A federal grand jury indicted Nevada physician Stephen Dubin, M.D., on six counts of healthcare fraud and conspiracy involving an alleged $95 million Medicare billing scheme tied to medically unnecessary amniotic wound allografts and kickbacks. This is the first prosecution by the newly active West Coast Health Care Fraud Strike Force, signaling expanded federal enforcement of wound care and skin substitute fraud in the western U.S. The case marks a significant escalation in DOJ scrutiny of CAMP billing practices and Anti-Kickback Statute violations.

The BTK read: This is a compliance watershed. The indictment lands on the heels of Congressional pressure on CMS for over-permissive CAMP coverage. Expect expanded audits of allograft billing across wound centers, SNFs, and mobile providers. Manufacturers should ensure their compliance and distribution frameworks can withstand heightened DOJ scrutiny. Smaller-cap CAMP-pure plays pricing in compliance risk this week.

Reimbursement | Aroa Biosurgery Gains U.S. Reimbursement Clarity for Symphony Wound Care

Aroa Biosurgery (ASX:ARX) has received reimbursement clarity in the U.S. market for its Symphony wound care product, opening a significant commercial opportunity in the advanced wound care segment. Symphony, which utilizes Aroa's proprietary MYRIAD extracellular matrix technology, stands to benefit from defined reimbursement pathways that are critical for hospital and outpatient adoption. This development is meaningful for the skin substitutes and advanced wound care market, as reimbursement certainty is a primary driver of product uptake among clinicians and health systems.

The BTK read: Aroa's clarity moment comes as the broader CAMP category faces pricing compression. Symphony's MYRIAD technology positioning it as distinct from traditional amniotic allografts is the differentiation story. Worth tracking Aroa's adoption trajectory against CAMP-pure players, particularly as compliance costs rise post-indictment. Also note: Aroa appointed Michael Lynskey, a 20-year advanced wound healing veteran and 11-year SNN veteran, as Chief Commercial Officer to lead global commercial growth strategy, and Mike Falcon as General Manager – US Commercial to drive U.S. commercial expansion. That's a signal they're building out seasoned commercial leadership to execute growth strategy in a higher-compliance environment.

Reimbursement | Orthofix Raises 2026 Guidance After Q2 Results, Medicare Reimbursement Restoration Drives Growth

Orthofix reported Q2 net sales of $210.9 million, up 4 percent reported and 5 percent pro forma constant currency, and raised full-year 2026 guidance for net sales and adjusted EBITDA following Medicare reimbursement restoration for bone growth stimulators. Global Spine Fixation and Limb Reconstruction generated double-digit constant currency growth reflecting strong international demand.

The BTK read: Orthofix's raise is a reimbursement tailwind story. Bone growth stimulators got coverage clarity, and the market responded. Contrast this against CAMP-pure players cutting guidance or holding flat. The bifurcation thesis holds: reimbursement clarity drives upside, reimbursement uncertainty drives downside. Limb Reconstruction double-digit growth is the piece worth isolating for lower limb salvage market health.

Clinical | Applied Biologics BioxHeal Enters Phase 3 Trial for Diabetic Foot Ulcers

Applied Biologics has received IRB approval to initiate a Phase 3 clinical trial for BioxHeal in diabetic foot ulcer treatment. This advancement signals growing clinical validation efforts in the biologics-based wound care segment, a competitive space that includes established skin substitutes and cellular/acellular matrix products. Positive Phase 3 outcomes could position BioxHeal as a future market entrant competing against leading CAMP products, with potential reimbursement pathway implications under CMS coverage frameworks.

The BTK read: Phase 3 advancement in wound care biologics is the clinical validation pipeline story. BioxHeal's entry into late-stage trials adds to the roster of next-generation competitors entering a market where reimbursement is tightening but unmet need remains real. Watch for how CMS treats novel biologics vs. traditional CAMP allografts on coverage determinations.

Clinical | MediWound Q2 2026 Earnings; EscharEx Phase III VALUE Trial Progressing

MediWound reported second-quarter 2026 revenue of $3.1 million and reaffirmed full-year guidance of $24–26 million. The company's EscharEx enzymatic debridement product for chronic wounds advanced in Phase III trials with interim assessment expected by Q1 2027. A master services agreement with Vericel under BARDA contract for NexoBrid marks continued commercialization of wound care biologics.

The BTK read: EscharEx Phase III progress is worth tracking for debridement-specific clinical validation. MediWound's BARDA partnership with Vericel signals government interest in novel wound care biologics beyond traditional skin substitutes. Watch the Q1 2027 interim readout.

Clinical | FibroBiologics Reports Q2 2026 Results, Advances Lead Wound Care Clinical Trial

FibroBiologics released its second quarter 2026 financial results while reporting progress on its clinical trial for its lead wound care candidate, a fibroblast-based therapy. The company continues to advance its pipeline in the wound care space. This is relevant to the advanced wound care and skin substitute market as cell-based therapies represent a growing segment competing with established products.

The BTK read: Cell-based therapy advancement is the differentiated play story. FibroBiologics' fibroblast approach is mechanistically distinct from allografts and represents the next wave of wound care competition if clinical data holds up. Track against CAMP-pure market share as reimbursement clarity emerges for novel modalities.

Investment | Vexev Raises $6M to Advance FDA Clearance of Robotic Vascular Ultrasound Platform

Australian medtech company Vexev has raised $6 million, bringing total funding to $19 million, to support FDA 510(k) clearance and U.S. commercialization of VxWave, an AI-powered robotic vascular ultrasound platform. The system demonstrated a 94 percent autonomous scanning success rate in a multi-site U.S. clinical study with U.S. Renal Care, operated by non-specialist staff. Beyond dialysis vascular access, Vexev plans to expand into peripheral artery disease imaging, a strategically significant adjacency for the BTK limb salvage and vascular intervention market.

The BTK read: Vexev's PAD imaging expansion is the adjacent market play. Vascular diagnostics automation at the point of care is a structural tailwind for limb salvage and vascular intervention markets facing staffing constraints. The 94% autonomous scanning success rate is the clinical proof point. Worth tracking for FDA clearance timing and U.S. launch trajectory, particularly as PAD procedure volume normalizes post-pandemic.

Clinical | Humacyte Pushes Real-World Trauma Data for Symvess with Investor Upside

Humacyte is advancing real-world clinical data for Symvess, its bioengineered human acellular vessel, in trauma vascular repair applications. The push highlights growing commercial momentum following FDA approval, with implications for limb salvage and vascular reconstruction in trauma settings. This positions Symvess as a differentiated asset in the lower limb vascular intervention market where synthetic and biological conduit options compete.

The BTK read: Symvess real-world data accumulation is the post-approval validation story. Bioengineered vessels represent the premium category in vascular reconstruction, with trauma and limb salvage as the lead use cases. Watch for publication of real-world outcomes and adoption rates in trauma centers and vascular surgery programs.

Market | Treace Medical Projects 2026 Revenue of $204M–$212M on New Product Launches

Treace Medical has outlined 2026 revenue guidance of $204M–$212M, driven by new product launches expanding its foot and ankle portfolio. The company's growth trajectory reflects continued investment in surgical solutions for foot and ankle conditions, a segment closely tied to diabetic limb salvage and BTK intervention markets. This guidance signals confidence in procedure volume recovery and portfolio expansion within the foot and ankle medtech space.

The BTK read: Treace's guidance is the foot and ankle procedure volume confidence signal. New product launches expanding the portfolio suggest sustained demand in diabetic limb salvage and prevention-of-amputation markets. Track for adoption of new solutions and whether procedure volumes normalize faster than broader orthopedic markets.

Market | Kuros Biosciences Reports 45% Growth Driving First Profitable Half-Year

Kuros Biosciences reported 45 percent revenue growth in H1 2026, achieving its first profitable half-year period. This milestone likely reflects strong commercial traction for their bone regeneration and biologics portfolio, which has adjacent relevance to lower limb reconstruction and wound care biologics markets. Profitability milestones in regenerative medicine signal increasing market adoption and competitive pressure on established wound care biologics players.

The BTK read: Kuros' path to profitability on 45% growth is the commercial traction story in bone regeneration. Adjacency to lower limb reconstruction and diabetic foot salvage is meaningful. Worth tracking as evidence that regenerative medicine and biologics-based solutions can hit scale and profitability in competitive medtech markets.

Market | Globus Medical Reports Strong Q2 2026 Results, Raises EPS Guidance

Globus Medical reported Q2 2026 revenue of $789.6 million (+6 percent reported, +9 percent organic excluding Nevro) with record non-GAAP EPS of $1.34, up 56 percent year over year. Adjusted EBITDA margin expanded 740 basis points to 35.4 percent. The company raised full-year 2026 non-GAAP EPS guidance to $4.95–$5.05, reflecting strong operational execution in its core musculoskeletal and spine businesses.

The BTK read: Globus Medical's raise is the large-cap spine and musculoskeletal confidence signal. A 56% EPS year-over-year increase and 740 bps margin expansion signal pricing power and operational leverage. The guidance raise reflects visibility into H2 execution. Worth tracking for whether larger players with lower limb reconstruction exposure (spinal implants, orthopedic systems) are seeing procedure volume or pricing tailwinds.

Market | BioStem Technologies Looks Beyond Wound Care Post-Nasdaq Listing

BioStem Technologies is planning to expand into new surgical specialties following its Nasdaq listing, broadening its regenerative medicine focus beyond wound care. The company also plans to relocate its headquarters to Boca Raton and significantly expand its workforce as it pursues what its CEO calls "aggressive plans to grow."

The BTK read: BioStem's post-listing diversification strategy is the adjacent expansion play. Moving beyond perinatal allografts into adjacent surgical specialties (likely orthopedic or reconstruction) signals management confidence that Nasdaq access will fund broader portfolio development. This is the inverse of CAMP-pure compression: smaller-cap regenerative medicine players are using public market access to expand addressable markets, not double down on single-category risk.

Capital | Teleflex Completes OEM Business Divestiture for $1.5B to Montagu, Kohlberg

Teleflex completed the sale of its OEM contract manufacturing business to private equity firms Montagu and Kohlberg for $1.5 billion in cash. The divested unit will be rebranded as Ingenyx and operate as a standalone medtech CDMO platform. Teleflex will deploy approximately $1.25 billion in after-tax proceeds toward $800 million in debt reduction and a $1 billion share repurchase program.

The BTK read: Teleflex's divestiture is the capital redeployment story. Teleflexis exiting OEM to focus on higher-margin core products and return capital. For wound care and vascular intervention suppliers, this signals OEM pricing pressure and consolidation in contract manufacturing, but Teleflex's focus shift may create portfolio opportunities in vascular devices and lower limb solutions.

Distribution | Cardinal Health Announces FY2026 Q4 Results with Guidance Raise

Cardinal Health reported fourth-quarter fiscal 2026 revenue of $63.7 billion, up 6 percent year-over-year, with non-GAAP diluted EPS of $2.91. The company guides FY27 EPS to $12.40–$12.60 and approved additional $5 billion share repurchase authorization. As a major medical distributor, Cardinal Health's performance impacts supply chain dynamics for wound care and vascular intervention products.

The BTK read: Cardinal Health's guidance raise reflects normalized distribution dynamics post-pandemic and solid healthcare spend growth. Supply chain for wound care and vascular is normalizing. Track for whether distributor margin pressure on CAMP products reflects the category-level compliance and pricing headwinds hitting manufacturers.

Market | Xtant Medical Q2 Revenue $23 Million, Weak Guidance Maintains Losses

Xtant Medical reported Q2 2026 revenue of $23 million versus $24.8 million pro forma in Q2 2025, with ongoing operating losses. The company continues commercializing Trivium Shaped pre-shaped bone grafts and expanding into wound care, but near-term sales headwinds persist despite operational innovations and expanded product offerings.

The BTK read: Xtant's stalled growth and continued losses is the cautionary tale for smaller-cap players trying to diversify from core bone graft into wound care. Expansion into adjacent categories is strategically sound but operationally expensive. Watch for whether management considers asset sales or partnerships to reduce burn rate.

Market | TELA Bio Reports Q2 Loss, Misses Revenue Estimates

TELA Bio reported a Q2 net loss while falling short of Wall Street revenue estimates, signaling continued commercial headwinds for the soft-tissue reconstruction company. TELA Bio competes in the biologic and synthetic mesh space relevant to abdominal wall and hernia repair, adjacent to lower limb reconstruction markets. Underperformance may prompt investors to reassess growth trajectories for differentiated biologic reconstruction platforms in the medtech sector.

The BTK read: TELA's miss is the soft-tissue reconstruction market reality check. Differentiated biologic products require clinical adoption and reimbursement clarity. Without both, growth stalls. Contrast against Kuros' profitability milestone and Orthofix's guidance raise — winners have clear reimbursement paths and clinical adoption curves, losers are fighting for share in crowded markets with pricing pressure.

Woundcare, Limb Salvage, Foot and Ankle and Vascular, all scored, indexed and monitored. Real-time capital signals. Curated news and alerts. AI-powered queries. The way no market intelligence platform has done before.

intelligence.belowtheknee.co/sign-up →

BTK Wound Care Fund (5D): +0.24% ITD | S&P 500: +0.53% | Dow Jones: −0.39% | NASDAQ: +0.45%

Top 5, five days:

Bottom 5, five days:

The BTK read: IART and ARX leading on reimbursement clarity and strategic positioning. BSX (Boston Scientific) holding up on Penumbra acquisition momentum and core vascular strength. SOLV benefiting from spinoff-focused investor interest and wound care upside isolation. GMED up on operational execution and margin expansion. Bottom tier: SNWV, SNOA, MDWD all down on CAMP exposure, enforcement risk, and lack of diversification. This is the bifurcation thesis made visible. Enforcement escalation is repricing CAMP-pure plays while reimbursement clarity and strategic diversification are rewarding winners.

Educational model portfolio. Not a real fund. Not investment advice. Performance is model-calculated and unaudited.

Next week: Humacyte (HUMX) scheduled to release Q2 2026 financial results on August 12 with investor webcast. Watch for Symvess trauma data discussion and late-stage trial updates (AV access hemodialysis, peripheral artery disease).

August 23–26 | Adelaide, Australia — Wounds Australia 2026 — Adelaide Convention Centre

September 10–11 | New Orleans, LA — IPAWS & Tissue Repair Summit (Kernexus) — The Ritz-Carlton (BTK Official Market Intelligence Partner)

September 14–16 | Louisville, KY — NAWCO HEAL Conference 2026

September 23–27 | Kuala Lumpur, Malaysia — WUWHS 2026 – World Union of Wound Healing Societies Congress — Kuala Lumpur Convention Centre

October 1–4 | Bengaluru, India — DFSICON 2026 — Hilton Garden Inn Bengaluru, Embassy Manyata Business Park

October 8–10 | New Delhi, India — ASVS–VSICON 2026 — Pullman & Novotel New Delhi Aerocity

October 15–18 | Las Vegas, NV — SAWC Fall 2026 — Caesars Palace

October 22–24 | Anaheim, CA — DFCon 2026 — JW Marriott

November 6 | Virtual — WoundCon Fall 2026

Early December (dates TBD) | San Antonio, TX — DFUpdate 2026 (ALPS)

December 9–12 | Phoenix, AZ — Desert Foot, Multi-Disciplinary Limb Salvage & Wound Care Conference

Not subscribed? newsletter.belowtheknee.co. Forward this to one person in your network who works in this space.

See you next week,

-Scott